

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Braj Bhushan Lohray, et al

10/007,109 Serial No.:

1624 Group No.

Filed: November 19, 2001

Examiner:

Kifle, Bruck

NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS

FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS

CONTAINING THEM

Attorney Docket No.: U 013701-9

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

We draw the attention of the Examiner to the references listed on the attached Form PTO-1449. Copies of the references are not required, because they were already filed in a U.S. application from which an earlier filing date is claimed in this application.

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

			LING	
☒	deposited Box 1450	with the United States Postal Service in a , Alexandria, VA 22313-1450.	n envelope addı	ressed to the Commissioner for Patents, P. O.
×	with suffi	37 C.F.R. 1.8(a) cient postage as first class mail.		as "Express Mail Post Office to Addressee" Mailing Label No
			MISSION	~
	transmitte	ed by facsimile to the Patent and Tradema	ork Office. to (7	
Date:	Septemb	per 15, 2004	Ja	net I. Cord or print name of person certifying)
*WARI	VING:			ne number of the "Express Mail" mailing label at the Express Mail mailing label thereon is an

"Since the filing of correspondence under § 1.10 without the Express Mail mailing lab oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

09/17/2004 SDIRETA1 00000103 10007109

(Information Disclosure Statement Short Form—page 1 of 1) 6-1a

01 FC:1806

180.00 OP

Respectfully submitted,

JANET I. CORD

c/o LADAS & PARRY, LLP

26 WEST 61st STREET NEW YORK, NEW YORK 10023 REG. NO. 33,778 (212) 708-1935

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Braj Bhushan Lohray, et al.

Application No.:

10/007,109

Group No.:

1624

O.

Filed: November 19, 2001

Examiner:

N/A

For:

NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Commissioner for Patents P. O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. 1.97(c))

37 C.F.R. 1.97: "(c) An information disclosure statement shall be considered by the Office if filed after the period specified in paragraph (b) of this section, provided that the information disclosure statement is filed before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application, and it is accompanied by one of:

- The statement specified in paragraph (e) of this section; or (1)
- The fee set forth in § 1.17(p)." (2)

"If a final action or notice of allowance is mailed in an application and later withdrawn, the application will be NOTE: considered as not having had a final action or notice of allowance mailed for purposes of considering an information disclosure statement." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

	MAIL	i
\boxtimes	deposited with the United States Postal Service in a	an envelope addressed to the Commissioner for Patents, P.
	Box 1450, Alexandria, VA 22313-1450.	
	37 C.F.R. 1.8(a)	37 C.F.R. 1.10* (<u>Preferred</u>)
⊠	with sufficient postage as first class mail.	as "Express Mail Post Office to Addres Mailing Label No(mandatory)
	TRANSP	×/
	transmitted by facsimile to the Patent and Tradema	Ak Office. to 703 872-9306
Date:	September 15, 2004	Signature
		Janet I. Cord (type or print name of person certifying)

^{*} Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

NOTE: 37 C.F.R. § 1.704(d): "A paper containing only an information disclosure statement in compliance with §§ 1.97 and 1.98 will not be considered a failure to engage in reasonable efforts to conclude prosecution (processing or examination) of the application under paragraphs (c)(6), (c)(8), (c)(9), or (c)(10) of this section if it is accompanied by a statement that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement. This thirty-day period is not extendable."

NOTE: "If information submitted during the period set forth in 37 C.F.R. 1.97(c) with a certification is used in a new ground of rejection on unamended claims, the next Office action will not be made final since in this situation it is clear that applicant has submitted the information to the office promptly after it has become known and the information is being submitted prior to a final determination on patentability by the Office. However, the information submitted with a certification can be used in a new ground of rejection and the next Office action made final, [i]f the new ground of rejection was necessitated by amendment of the application by applicant. Where the information is submitted during this period with a fee, the examiner may use the information submitted, e.g., printed publication or evidence of public use, and make the next Office action final whether or not the claims have been amended, provided that no other new ground of rejection which was not necessitated by amendment to the claims is introduced by the examiner. See MPEP 706.07(a). If a new ground of rejection is introduced that is neither necessitated by an amendment to the claims nor based on the information submitted with the fee set forth in 37 C.F.R. 1.17(p), the Office action shall not be made final. Notice of April 20, 1992 (1138 O.G. 37-41, 39).

WARNING:

"A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as failing to present good and sufficient reasons, since 37 C.F.R. 1.97 provides adequate recourse for the timely submission of prior art for consideration by the examiner." Notice of July 6, 1992 (1141 O.G. 63). But see § 103(b) and (c), limited suspension of action in a continued prosecution application (CPA) filed under § 1.53(d) and in a request for continued examination (RCE) under § 1.114.

WARNING:

No extension of time can be had under 37 C.F.R. 1.136(a) or (b) for filing an IDS. 37 C.F.R. 1.97(f).

TIME OF TRANSMITTAL OF ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

- 1. The information disclosure statement transmitted herewith is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:
 - (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,

whichever occurs first.

STATEMENT OR FEE

2. Accompanying this transmittal is

(check either A or B below)

A. [] a statement as specified in 37 C.F.R. 1.97(e).

OR

B. [X] the fee set forth in 37 C.F.R. 1.17(p) for submission of an information disclosure statement under § 1.97(c). (\$180.00).

METHOD OF PAYMENT OF FEE

3. [X] Attached is a check in the amount of \$\frac{180.00}{}.

A duplicate of this request	is attached.
If any additional fees are due, please charge	e Account <u>12-0425</u> .
	SIGNATURE OF PRACTITIONER
Reg. No. 33,778	Janet I. Cord
	(type or print name of practitioner)
Tel. No.: (212) 708-1935	
	P.O. Address
Customer No.: 01400	
	c/o Ladas & Parry LLP
	26 West 61st Street
	New York, N.Y. 10023

FORM PTO-1449

U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.	SERIAL NO.			
U 013701-9	10/007,109			
APPLIC	ANT			
Braj Bhushan LC	HRAY, et al			
FILING DATE	GROUP			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

applicant.

LLツ	STATEMENT BY APPLICANT			Braj Bhushan LOHRAY, et al					
17 200k	(U)	se several sheets if necessary)			FILING DATE		GROUP 1624		
(Use several sheets if necessary)				Novemb	er 19, 2001				
TANGENE	ERENCI	DESIGNATION	U	.S. PATEN	T DOCUME	NTS			
XAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME			FILING DATE IF APPROPRIATE		
	AA	5,593,970	01/1997	Attardo,	et al.				
	AB								
	AC								
	AD								
	AE								
	AF								
	AG								
	АН								
	Al								
	AJ								
	<u> </u>	FOREIGN PATENT DOCUMENTS							
	DOCUMENT		DATE	201	UNTRY		TRANSLATION		
		NUMBER	DATE			YES	NO		
	AK	0903343	03/1999		EP				
	AL	00/26200	05/2000		wo				
	AM	0916651	05/1999		EP				
	AN	1026149	08/2000		EP				
	AO		 						
	AP		<u> </u>						
		OTHER AF				ent Dates, Etc.)	40 in portionler		
	AQ	compounds RN 156	994: 482641 of Teto 3335-15-9, RN 1563	35-16-9, F	100335				
	AR								
	AS	CAS abstract AN 1972: 526535 of Tetrahedron Letters (1972), (29), 2911-14 in particular compound RN 38291-54-2							
EXAMINE	R				tion is in conformance with MPEP 609; Draw line through				